33252-62-9Relevant articles and documents
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00242; 00342, (2020/09/27)
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: Synthesis, structure-activity relationships, and biological activities
Lu, Tiangong,Goh, Aik Wye,Yu, Mingfeng,Adams, Julian,Lam, Frankie,Teo, Theodosia,Li, Peng,Noll, Ben,Zhong, Longjin,Diab, Sarah,Chahrour, Osama,Hu, Anran,Abbas, Abdullahi Y.,Liu, Xiangrui,Huang, Shiliang,Sumby, Christopher J.,Milne, Robert,Midgley, Carol,Wang, Shudong
, p. 2275 - 2291 (2014/04/17)
ON01910.Na is a highly effective anticancer agent that induces mitotic arrest and apoptosis. Clinical studies with ON01910 in cancer patients have shown efficacy along with an impressive safety profile. While ON01910 is highly active against cancer cells,
PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES
-
Page/Page column 68, (2012/12/13)
Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).